Introduction
Methods
Design
Ethics
Patients
Study parameters
BT drugs
Injectors
Ultrasound guidance
Anatomical guidance
Statistics
Results
Frequency
Reproducibility
Severity
Duration
Predictability
Factor | Patients with dysphagia | Patients without dysphagia | Significance |
---|---|---|---|
Female sex [n] | 13 | 39 | Chi-square test p = 0.104 |
Male sex [n] | 2 | 21 | |
Patient age [years] | 56.4 ± 11.5 | 61 ± 12 | Unpaired T-test p = 0.191 |
Total number of injection series [n] | 63 | 263 | N/A |
Injection series per patient and year [n] | 4.1 ± 0.8 | 4.1 ± 0.8 | Unpaired T-test p = 0.979 |
BT total dose [uMU] | 269.9 ± 69.9 | 315.5 ± 103.4 | Wilcoxon-ranksum-test p < 0.001 |
BT dose in SCM [uMU] | 37.9 ± 16.5 | 40.8 ± 19.2 | Wilcoxon-ranksum-test p = 0.242 |
BT dose in SCM + SCA [uMU] | 35.2 ± 15.5 | 37.9 ± 18.5 | Wilcoxon-ranksum-test p = 0.226 |
BT therapy with unilateral SCM injections [n] | 41 | 159 | Chi-square test p = 0.498 |
BT therapy with bilateral SCM injections [n] | 22 | 104 | |
BT therapy with ultrasound guidance [n] | 21 | 96 | Chi-square test p = 0.638 |
BT therapy with anatomical guidance [n] | 42 | 167 | |
BT therapy with ONA + INCO [n] | 55 | 228 | Chi-square test p = 0.898 |
BT therapy with ABO [n] | 8 | 35 |